

Applicant: Boyle et al.  
USSN: 09/211,297  
Docket No. A-451F

~~§ 112, c3~~ 42. (new) The antibody or fragment of Claim 41 prepared by immunization of a transgenic animal capable of producing human antibodies.

~~§ 112, c3~~ 43. (new) The composition of Claim 37 wherein the antibody or fragment thereof binds to an epitope on the extracellular domain or to an epitope on a fragment of the extracellular domain of an osteoprotegerin binding protein.

43

~~§ 112, c4~~ 44. (new) The antibody or fragment of Claim 44 wherein the epitope comprises the BB' loop.

43

~~§ 112, c4~~ 45. (new) The antibody or fragment of Claim 44 wherein the epitope comprises the EF loop.

45

~~§ 112, c6~~ 46. (new) The composition of any of Claims 37-47 further comprising a bone morphogenic factor selected from the group consisting of BMP-1 to BMP-12, transforming growth factor- $\beta$ , a transforming growth factor- $\beta$  family member, a fibroblast growth factor selected from the group consisting of FGF-1 to FGF-10, an interleukin-1 inhibitor, a TNF $\alpha$  inhibitor, parathyroid hormone, an E series prostaglandin, a bisphosphonate, or a bone-enhancing mineral.

open to  $\beta$  1-10?

REMARKS

See p. 4-4

Claims 1-36 are canceled without prejudice and new Claims 37-47 have been added. The new claims are directed to a composition comprising an antibody which binds to an osteoprotegerin binding protein with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant, wherein the antibody is present in an amount effective to inhibit bone resorption. Support for the new claims is found at pp. 17-19 and 23 of the specification and also in Example 11 at pp. 46 and 47. It is submitted that the new claims do not introduce new matter and entry of same is respectfully requested.

Upon entry of the amendments, Claims 37-47 are in condition for allowance and an early notice thereof is solicited.

Respectfully submitted,

Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: MARCH 22, 1993

Please send all future correspondence to:  
U.S. Patent Operations/ RBW  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1789